It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Basilea Pharmaceutica AG (BSLN) CHF1 (Regd)

Sell:46.00 CHF Buy:46.80 CHF Change: 0.34 CHF (0.73%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Sell:46.00 CHF
Buy:46.80 CHF
Change: 0.34 CHF (0.73%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Sell:46.00 CHF
Buy:46.80 CHF
Change: 0.34 CHF (0.73%)
Market closed |  Prices as at close on 18 June 2021 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Contact details

Address:
Grenzacherstrasse 487
BASEL
4058
Switzerland
Telephone:
+41 (61) 6061111
Website:
www.basilea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BSLN
ISIN:
CH0011432447
Market cap:
605.36 million CHF
Shares in issue:
11.87 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • Domenico Scala
    Chairman of the Board of Directors
  • David Veitch
    Chief Executive Officer, Member of the Management Committee
  • Thomas Werner
    Vice Chairman of the Board of Directors
  • Adesh Kaul
    Member of the Management Committee, Chief Financial Officer
  • Gerrit Hauck
    Member of the Management Committee, Chief Technology Officer
  • Laurenz Kellenberger
    Member of the Management Committee, Chief Scientific Officer
  • Damian Heller
    General Counsel, Corporate Secretary
  • Ursula Eberhardt
    Head of Global Human Resources
  • Savitha Ram Moorthi
    Head of Global Quality Management
  • Marc Engelhardt
    Member of the Management Committee, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.